New report estimates nearly 19 million cancer survivors in the US by 2024

Growing, aging population & increased survival driving trend

2014-06-01

(Press-News.org) ATLANTA – June 1, 2014 – The number of cancer survivors in the United States, currently estimated to be 14.5 million, will grow to almost 19 million by 2024, according to an updated report by the American Cancer Society. The second edition of Cancer Treatment & Survivorship Facts & Figures, 2014-2015 and an accompanying journal article published in CA: A Cancer Journal for Clinicians find that even though cancer incidence rates have been decreasing for ten years, the number of cancer survivors is growing. This is the result of increases in cancer diagnoses driven by the aging and growth of the population, as well as the fact that people are living longer with cancer because of earlier cancer detection and more effective treatments.

The three most common cancers among males living with a history of cancer in 2014 are prostate (43%), colorectal (9%), and melanoma (8%). Among women in 2014, the three most common cancers are breast (41%), uterine (8%), and colorectal (8%). While lung cancer is the leading cause of cancer death and the second most commonly diagnosed cancer in both men and women, a low survival rate makes it the number eight cancer site represented among survivors. The distribution of prevalent cancers is expected to be largely unchanged in 2024.

Other selected findings:

The majority of cancer survivors (64%) were diagnosed five or more years previously, and 15% were diagnosed 20 or more years ago.

Nearly one-half of cancer survivors (46%) are aged 70 years or older, while one in 20 (5%) is under age 40.

The age distribution of cancer survivors varies substantially by cancer type. For example, the majority of prostate cancer survivors (62%) are aged 70 and older, whereas less than one-third (32%) of melanoma survivors are in this age group.

By January 1, 2024, it is estimated that the population of cancer survivors will increase to nearly 19 million individuals (9.3 million males and 9.6 million females).

In addition to prevalence estimates, the reports also include data on cancer treatment patterns, survival, and information on common short- and long-term effects of cancer and its treatment for eleven selected cancers. Cancer Treatment and Survivorship Facts & Figures also contains sections on the effects of cancer and its treatment, impairment-driven cancer rehabilitation, palliative care, long term survivorship, the benefits of healthy behaviors, and resources for cancer survivors from the American Cancer Society and other organizations.

"The growing number of cancer survivors in the U.S. makes it increasingly important to understand the unique medical and psychosocial needs of survivors," said Carol DeSantis, MPH, American Cancer Society epidemiologist and lead author of the reports. "Despite the fact that awareness of survivorship issues has increased, cancer survivors face numerous, important hurdles created by a fractured health care system, poor integration of survivorship care, and financial and other barriers to quality care, particularly among the medically underserved. An important first step in addressing these challenges is to identify 'best practices' for the delivery of quality post-treatment cancer care."

INFORMATION: Article: DeSantis, CE; Lin, CC; Mariotto, AB, et al. (2014), Cancer Treatment and Survivorship Statistics, 2014. CA: A Cancer Journal for Clinicians. Published online ahead of print June 1, 2014. doi: 10.3322/caac.21235. For more information and resources, see http://www.cancer.org/survivors

ELSE PRESS RELEASES FROM THIS DATE:

Reducing emissions will be the primary way to fight climate change, UCLA-led study finds

2014-06-01

Forget about positioning giant mirrors in space to reduce the amount of sunlight being trapped in the earth's atmosphere or seeding clouds to reduce the amount of light entering earth's atmosphere. Those approaches to climate engineering aren't likely to be effective or practical in slowing global warming. A new report by professors from UCLA and five other universities concludes that there's no way around it: We have to cut down the amount of carbon being released into the atmosphere. The interdisciplinary team looked at a range of possible approaches to dissipating ...

ALTTO test of dual HER2 blockade finds single agent remains the gold standard

2014-06-01

CHICAGO — June 1, 2014 — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th annual meeting of the American Society of Clinical Oncology (ASCO). MULTIMEDIA ALERT: Video and audio are available for download on the Mayo Clinic News Network. Results of the phase III clinical trial, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization study), demonstrated that adding ...

The ethics of knowing where to stop treatment in a sick and elderly patient

2014-06-01

An Emeritus Professor of medical ethics at Imperial College London will deliver a presentation at this year's Euroanaesthesia meeting titled 'Escalating care for the comorbid elderly-where do we stop?". Raanan Gillon, who is President of the UK's Institute of Medical Ethics, will argue that a patient's age should not in itself be considered an ethically relevant criterion for deciding 'where to stop'. Acknowledging that there is a morally plausible counter-argument – known in the UK as 'the fair innings argument'- according to which scarce life prolonging resources should ...

Study of 55 million people adds further evidence that patients admitted to hospital at weekends have higher mortality

2014-06-01

A systematic review and meta-analysis of hospital data worldwide, presented as this year's Euroanaesthesia meeting in Stockholm, adds further evidence that patients admitted to hospital at weekends have higher mortality than those admitted on weekdays. The study is by Dr Hiroshi Hoshijima, Tohoku University, Sendai, Japan, and colleagues. The analysis included 72 studies from various world regions, covering 55,053,719 participants. The authors found that weekend admission was associated with increased morality of between 15% and 17% depending on the statistical technique ...

Risk of death highest following surgery in afternoons, at weekends, and in February

2014-06-01

New research presented at this year's Euroanaesthesia show that on weekends, in the afternoons and in February are the times when the risk of death following surgery is the highest. The research is by Dr Felix Kork and Professor Claudia Spies, Charité - University Medicine Berlin, Germany and colleagues. Hospital mortality is subject to day-night, weekly and seasonal variability. This has been shown for various populations, settings, and in different regions of the world. However, a cyclic influence on hospital mortality has not been shown in patients after surgery. ...

Poor coverage of specific gene sets in exome sequencing gives cause for concern

2014-06-01

With services based on exome sequencing becoming affordable to patients at a reasonable price, the question of the quality of the results provided has become increasingly important. The exome is the DNA sequence of genes that are translated into protein. These protein-coding regions contain most of the currently-known disease-causing genetic mutations. The American College of Medical Genetics and Genomics (ACMG) has recommended the reporting to patients of clinically actionable incidental genetic findings in the course of clinical exome testing. Specifically, mutations ...

Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease

2014-05-31

A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195). In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma kinase (ALK) gene, and subsequently was granted regular approval in 2013. The drug also has shown dramatic responses in ...

Results in Phase I trial of OMP-54F28, a Wnt inhibitor targeting cancer stem cells

2014-05-31

At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials are now open for OMP-54F28 (FZD8-Fc) in combinations with standard therapy for pancreatic, ovarian and liver cancers, ...

ASCO: One step closer to a breath test for lung cancer

2014-05-31

Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present. "This could totally revolutionize lung cancer screening and diagnosis. The perspective here is the development of a non-traumatic, easy, cheap approach to early detection and differentiation of lung cancer," ...

ALK, ROS1 and now NTRK1: Study shows prevalence of new genetic driver in lung cancer

2014-05-31

A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation. The current study reports the prevalence of the NTRK1 mutation in an unselected population of 450 lung cancer samples, with >1% percent of patients testing positive. This and other work from Dr. Doebele's group forms the basis of a phase 1 clinical trial targeting NTRK1 mutations in advanced solid ...

New report estimates nearly 19 million cancer survivors in the US by 2024

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: